Health Care·Biotechnology·$28.9B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.55 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.55 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed concerns about current market conditions. They emphasized a commitment to enhancing their service offerings.
Management did not provide specific guidance for future performance.
The company is focusing on improving operational efficiencies.
Natera's earnings report showed a loss per share of $0.55, which may raise concerns among investors about the company's profitability. The stock reacted negatively, dropping 3.06% following the announcement. The lack of revenue details and guidance could lead to uncertainty about the company's future performance.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
WILLIS TOWERS WATSON
Aug 6, 2018